Folha de evidência científica · Judici Cannabis

Cannabis reduz tiques na síndrome de Tourette

Canabinoides (THC) reduzem tiques no Tourette? — RCTs pequenos e séries mostram redução de tiques; evidência ainda limitada.

força líquida 0.57 consenso 92 · consenso forte Consolidada 28 estudos · 17 apoiam · 2 refutam 100% ≥2020 57% alto nível

📐 Números que convencem

reduz sintomas de ansiedade (SMD=-0.40) e PTSD (SMD=-2.60) em RCTs

Cannabis and cannabinoids for the treatment of mental and substance use disorders and symptoms: A systematic review and meta-analysis of experimental and observational studies. (2026) · DOI: 10.1016/j.psychres.2026.117380

reduz YGTSS em média 13.29 pontos e PUTS em média 4.09 pontos

Cannabis for tic control: a systematic review and meta-analysis of its efficacy in Tourette syndrome management. (2026) · DOI: 10.1016/j.neuroscience.2026.05.044

reduz frequência de crises entre 30% e 50%

Cannabinoids for Medical Purposes in Children: A Living Systematic Review. (2025) · DOI: 10.1111/apa.70140

moderado efeito significativo com SMD: -0.61

Effects of Different Cannabinoid Formulations on Anxiety-Related Disorders, and Tourette Syndrome: A Systematic Review and Meta-Analysis. (2025) · DOI: 10.1177/25785125251378242

aumento na aptidão para dirigir de 55.8% para 71.8% com nabiximols

The Effect of Nabiximols on Driving Ability in Adults with Chronic Tic Disorders: Results of a Substudy Analysis of the Double-Blind, Randomized, Placebo-Controlled CANNA-TICS Trial. (2024) · DOI: 10.1089/can.2023.0114

significativo efeito de THC 10% no PUTS, SUDS e CGI-I vs placebo

A Double-Blind, Randomized, Controlled Crossover Trial of Cannabis in Adults with Tourette Syndrome. (2023) · DOI: 10.1089/can.2022.0091

✅ Evidências que apoiam (17)

apoiaCannabis for Tic Control: A Systematic Review and Meta-Analysis of Its Efficacy in Tourette Syndrome Management

Mann DGS, Gadelmawla DAF, Dway DA, Fayaz FH, Kebede DEA, Varadharaj NK et al. (2024), Preprints.org · meta analise · força 1.00 · DOI
reduz a gravidade dos tiques

apoiaCannabis and cannabinoids for the treatment of mental and substance use disorders and symptoms: A systematic review and meta-analysis of experimental and observational studies.

Bharat C, Huang X, Campbell G, Tisdale C, Glasgow S, Nielsen S et al. (2026) · meta analise · força 1.00 · DOI
reduz sintomas de ansiedade (SMD=-0.40) e PTSD (SMD=-2.60) em RCTs

apoiaCannabis for tic control: a systematic review and meta-analysis of its efficacy in Tourette syndrome management.

Mann GS, Gadelmawla AF, Dway A, Fayaz FH, Kebede EA, Varadharaj NK et al. (2026) · meta analise · força 1.00 · DOI
reduz YGTSS em média 13.29 pontos e PUTS em média 4.09 pontos

apoiaCannabinoids for Medical Purposes in Children: A Living Systematic Review.

Chhabra M, Paul A, Abulannaz O, Lê ML, Mansell H, Finkelstein Y et al. (2025) · revisao sistematica · força 1.00 · DOI
reduz frequência de crises entre 30% e 50%

apoiaEffects of Different Cannabinoid Formulations on Anxiety-Related Disorders, and Tourette Syndrome: A Systematic Review and Meta-Analysis.

Raminelli AO, Simei JLQ, Guimarães FS, Zuardi A, Hallak JEC, Crippa JA et al. (2025) · meta analise · força 1.00 · DOI
moderado efeito significativo com SMD: -0.61

apoiaArrhythmias and cannabis use: A comprehensive overview.

Paulraj S, Upreti P, Tamirisa K, Batnyam U (2025) · revisao sistematica · força 0.98 · DOI
associação significativa entre uso de cannabis e arritmias

apoiaThe Effect of Nabiximols on Driving Ability in Adults with Chronic Tic Disorders: Results of a Substudy Analysis of the Double-Blind, Randomized, Placebo-Controlled CANNA-TICS Trial.

Müller-Vahl KR, Pisarenko A, Ringlstetter R, Cimpianu CL, Fremer C, Weidinger E et al. (2024) · ensaio clinico rct · força 0.93 · DOI
aumento na aptidão para dirigir de 55.8% para 71.8% com nabiximols

apoiaA Double-Blind, Randomized, Controlled Crossover Trial of Cannabis in Adults with Tourette Syndrome.

Abi-Jaoude E, Bhikram T, Parveen F, Levenbach J, Lafreniere-Roula M, Sandor P (2023) · ensaio clinico rct · força 0.93 · DOI
significativo efeito de THC 10% no PUTS, SUDS e CGI-I vs placebo

apoiaA Pilot Randomized Placebo-Controlled Crossover Trial of Medicinal Cannabis in Adolescents with Tourette Syndrome.

Efron D, Taylor K, Chan E, Payne JM, Prakash C, Lee KJ et al. (2025) · ensaio clinico rct · força 0.93 · DOI
três participantes melhoraram muito com MC vs um com placebo

apoiaTetrahydrocannabinol and Cannabidiol in Tourette Syndrome.

Mosley PE, Webb L, Suraev A, Hingston L, Turnbull T, Foster K et al. (2023) · ensaio clinico rct · força 0.93 · DOI
reduz escore total de tiques em 8.9 vs 2.5 no grupo placebo

apoiaLicensed Medical Cannabis Use in Gilles de la Tourette Syndrome: A Retrospective Long-term Follow-Up.

Anis S, Zalomek C, Korczyn AD, Lassman S, Rosenberg A, Gurevich T (2024) · coorte · força 0.75 · DOI
sujeitos relatam melhora no controle dos sintomas

apoiaThe Use of Cannabis-Based Medicine in Selected Neurological Disorders.

Szejko N, Saramak K, Müller-Vahl KR (2026) · revisao narrativa · força 0.38 · DOI
melhora tics e comorbidades psiquiátricas em síndrome de Tourette

⚠️ Evidências que refutam (2) — transparência

refutaEfficacy of cannabinoids in neurodevelopmental and neuropsychiatric disorders among children and adolescents: a systematic review.

Rice LJ, Cannon L, Dadlani N, Cheung MMY, Einfeld SL, Efron D et al. (2024) · força 0.98 · DOI

refutaMedical cannabis utilization in children - a study based on a nationwide cohort.

Treves N, Yakirevich-Amir N, Allegaert K, van den Anker JN, Kohn E, Berlin M et al. (2025) · força 0.75 · DOI

Folha gerada em 28/09/2026 pela plataforma Judici Cannabis. Evidência real e rastreável (DOI). 9 estudo(s) de contexto (revisões/mecanístico) não listados. Força líquida = apoio − refutação ponderado; maturidade por regras explícitas. Não substitui aconselhamento médico/jurídico.

← Voltar à Evidência